Drug Profile
Sirolimus albumin bound - Abraxis Bioscience
Alternative Names: ABI-009; albumin-bound rapamycin; FYARRO; Nab-rapamycin; Nab-sirolimus; TARZIFYXLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Abraxis BioScience
- Developer Aadi Bioscience; Children's Oncology Group; Mirati Therapeutics; National Cancer Institute (USA); Ochsner Clinic Foundation; Seattle Children's Hospital; University of Washington
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Perivascular epithelioid cell tumours
- Phase II Endometrial cancer; Glioblastoma; Glioma; Leigh disease; Neuroendocrine tumours; Solid tumours
- Phase I/II Bladder cancer; Colorectal cancer; Sarcoma; Soft tissue sarcoma
- Phase I Epilepsy; Non-small cell lung cancer; Pulmonary arterial hypertension
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 14 Dec 2023 Interim efficacy and adverse events data from the phase II trial in Solid tumours released by Aadi Bioscience
- 31 Oct 2023 Phase-II clinical trials in Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT05997056)